Trial
NCT04419909
Retreatment With CTL019/CTL119
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Pennsylvania
Collaborators
—
Condition
Lymphoma, B-Cell
Intervention
CD19 redirected autologous T cells (CTL019 or CTL119 cells)
Why stopped
Lack of Eligible Subjects
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-22